Canadian Association of Pediatric Ophthalmology

ROP, IOLs and PFV, Terson syndrome, Botulinum toxin for corneal disease

Saturday June 15, 2013, 1545-1715
Côte St. Luc

Objectives
At the end of this session, participants will be able to:

  • Describe new concepts on the screening, evaluation and treatment of ROP.
  • Increase knowledge of Terson syndrome, the role of IOLs in PFV, and the impact of recent therapies such as anti-VEGF for ROP and Botulinum toxin for corneal disease.

Guest
Jonathan M. Holmes, MD 		Moderator
Patrick Hamel

1545Botulinum toxin-induced ptosis in the management of corneal ulceration in anaesthetic corneas
Christopher Lyons, Elham Saud, Jane C. Gardiner, Ashley S. Ko
1553Discussion
1600Outcomes of persistent fetal vasculature cataracts with primary intraocular lens implantation
Lisa Lagrou, William F. Astle
1608Discussion
1615Terson syndrome in children
Jesia Hasan, Ahmed Basheikh, Fabricio Goncalves, Ayesha Khan
1623Discussion
1630Treatment outcomes of combined laser with intravitreal bevacizumab versus laser
Hayat A. Khan, Mohamed K. Tameesh
1638Discussion
1645Treatment alone in cases of aggressive posterior retinopathy of prematurity (APROP)
1652Discussion
1700Seminal Canadian recommendations for evidence based examination of neonates for retinopathy of prematurity (SCREEN-ROP): provisional new guidelines
Kourosh Sabri, Kaitlyn Whelan, Virginia Viscardi, Niraj Patel, Wendy Seidlitz, Forough Farrokhyar, Sandesh Shivananda, Anna Ells, Shoo Lee
1708Discussion
1715Closing remarks

Jonathan M. Holmes
Jonathan M. Holmes, MD